Recommended standards for reports dealing with lower extremity ischemia: revised version Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus al. Peripheral Arterial Disease as an Independent Predictor for Excess Stroke Morbidity and Mortality in Primary-Care Patients: 5-Year Results of the getABI Study, Helv Chir Acta J Vasc Surg J Vasc Surg Int J Epidemiol Ann Intern Med Cerebrovasc Dis, vol.2126452014129, pp.499-533517, 1954. ,
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC), JAMA J Vasc Surg, vol.29531, pp.180-189, 2000. ,
An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), Annals of Vascular Diseases, vol.8, issue.4, pp.343-57, 2015. ,
DOI : 10.3400/avd.tasc.15-01000
Long vein transplantation in treatment of ischemia caused by arteritis], Rev Chir, vol.70, pp.206-241, 1951. ,
The use of expanded microporous polytetrafluoroethylene for limb salvage: a preliminary report, Surgery, vol.79, pp.485-91, 1976. ,
Graft type for femoro-popliteal bypass surgery, Cochrane Database Syst. Rev, vol.15, issue.2: ,
DOI : 10.1111/j.1524-475X.2007.00294.x
Randomized Study of Noninferiority Comparing Prosthetic and Autologous Vein Above-Knee Femoropopliteal Bypasses, Annals of Vascular Surgery, vol.31, pp.99-104, 2016. ,
DOI : 10.1016/j.avsg.2015.07.047
A meta-analysis to compare Dacron versus polytetrafluroethylene grafts for above-knee femoropopliteal artery bypass, Journal of Vascular Surgery, vol.60, issue.2, pp.506-521, 2014. ,
DOI : 10.1016/j.jvs.2014.05.049
Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses, Surgery, vol.126, issue.4, pp.594-602, 1999. ,
DOI : 10.1016/S0039-6060(99)70110-8
Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions, Journal of Vascular Surgery, vol.3, issue.1, pp.104-114, 1986. ,
DOI : 10.1016/0741-5214(86)90073-X
Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial, Journal of Vascular Surgery, vol.31, issue.3, pp.417-442, 2000. ,
DOI : 10.1067/mva.2000.103238
A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: A prospective randomized Department of Veterans Affairs cooperative study, Journal of Vascular Surgery, vol.32, issue.2, pp.268-77, 2000. ,
DOI : 10.1067/mva.2000.106944
Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency, Journal of Vascular Surgery, vol.44, issue.3, pp.510-517, 2006. ,
DOI : 10.1016/j.jvs.2006.04.054
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial, Lancet Lond Engl, vol.366, issue.05, pp.1925-1959, 2005. ,
Perkutane Rekanalisation chronischer arterieller Verschl??sse mit einem neuen Dilatationskatheter, DMW - Deutsche Medizinische Wochenschrift, vol.99, issue.49, pp.2502-2512, 19461974. ,
DOI : 10.1055/s-0028-1108161
Quantitative assessment of the conformational change in the femoropopliteal artery with leg movement, Catheterization and Cardiovascular Interventions, vol.48, issue.Pt 1, pp.787-98, 2009. ,
DOI : 10.1097/01.RVI.0000151260.74519.CA
Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: A meta-analysis, Journal of Vascular Surgery, vol.47, issue.2, pp.461-470, 2008. ,
DOI : 10.1016/j.jvs.2007.07.059
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery, New England Journal of Medicine, vol.354, issue.18, pp.1879-88, 2006. ,
DOI : 10.1056/NEJMoa051303
Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions, Catheterization and Cardiovascular Interventions, vol.83, issue.7, pp.1090-1095, 2009. ,
DOI : 10.1097/01.RVI.0000151260.74519.CA
Femoral and popliteal arteries: reanalysis of results of balloon angioplasty., Radiology, vol.183, issue.3, pp.767-71, 1992. ,
DOI : 10.1148/radiology.183.3.1294068
Femoropopliteal angioplasty. Factors influencing long-term success, Circulation, vol.83, pp.70-80, 1991. ,
PTA versus Palmaz Stent Placement in Femoropopliteal Artery Obstructions: A Multicenter Prospective Randomized Study, Journal of Vascular and Interventional Radiology, vol.12, issue.1, pp.23-31, 2001. ,
DOI : 10.1016/S1051-0443(07)61397-9
Randomized Study to Compare PTA Alone versus PTA with Palmaz Stent Placement for Femoropopliteal Lesions, Journal of Vascular and Interventional Radiology, vol.12, issue.8, pp.935-977, 2001. ,
DOI : 10.1016/S1051-0443(07)61572-3
Balloon Angioplasty Combined with Primary Stenting Versus Balloon Angioplasty Alone in Femoropopliteal Obstructions: A Comparative Randomized Study, CardioVascular and Interventional Radiology, vol.20, issue.6, pp.420-425, 1997. ,
DOI : 10.1007/s002709900186
Nitinol Self-Expanding Stents vs. Balloon Angioplasty for Very Long Femoropopliteal Lesions, Journal of Endovascular Therapy, vol.21, issue.1, pp.34-43, 2014. ,
DOI : 10.1583/13-4399MR.1
High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty, Journal of Vascular Surgery, vol.25, issue.1, pp.74-83, 1997. ,
DOI : 10.1016/S0741-5214(97)70323-9
Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in Length: The Femoral Artery Stenting Trial (FAST), Circulation, vol.116, issue.3, pp.285-92, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.107.689141
Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the RESILIENT Randomized Trial, Circulation: Cardiovascular Interventions, vol.3, issue.3, pp.267-76, 2010. ,
DOI : 10.1161/CIRCINTERVENTIONS.109.903468
The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Prot??g?? EverfLex NitInol STent SYstem II (DURABILITY II), Journal of Vascular Surgery, vol.58, issue.1, pp.73-83, 2013. ,
DOI : 10.1016/j.jvs.2012.12.066
One-year Clinical Outcome after Primary Stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D Femoropopliteal Lesions (The STELLA ???STEnting Long de L'Art??re f??morale superficielle??? Cohort), European Journal of Vascular and Endovascular Surgery, vol.44, issue.4, pp.432-473, 2012. ,
DOI : 10.1016/j.ejvs.2012.07.015
Long-Term Primary Patency Rate After Nitinol Self-Expandable Stents Implantation in Long, Totally Occluded Femoropopliteal (TASC II C & D) Lesions, Heart, Lung and Circulation, vol.26, issue.6, pp.604-615, 2017. ,
DOI : 10.1016/j.hlc.2016.09.011
Results of the Prot??g?? EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions, Journal of Vascular Surgery, vol.54, issue.4, pp.1042-50, 2011. ,
DOI : 10.1016/j.jvs.2011.03.272
Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients, J Cardiovasc Surg, 2016. ,
Prevalence and clinical impact of stent fractures after femoropopliteal stenting, Journal of the American College of Cardiology, vol.45, issue.2, pp.312-317, 2005. ,
DOI : 10.1016/j.jacc.2004.11.026
Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial, Circulation: Cardiovascular Interventions, vol.8, issue.5, 2015. ,
DOI : 10.1161/CIRCINTERVENTIONS.113.000937
Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses, Catheterization and Cardiovascular Interventions, vol.20, issue.4, pp.611-618, 2011. ,
DOI : 10.1097/00005344-199212000-00009
Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease, Journal of Vascular Surgery, vol.54, issue.3, pp.714-735, 2011. ,
DOI : 10.1016/j.jvs.2011.03.216
Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease, Journal of Vascular Surgery, vol.58, issue.2, 2013. ,
DOI : 10.1016/j.jvs.2013.01.050
Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia, Circulation, vol.79, issue.6, pp.1374-87, 1989. ,
DOI : 10.1161/01.CIR.79.6.1374
Restenosis after percutaneous transluminal coronary angioplasty. A histopathological study using autopsied hearts., Japanese Circulation Journal, vol.54, issue.1, pp.43-56, 1990. ,
DOI : 10.1253/jcj.54.43
Hyperplasia of the arterial intima due to smooth muscle cell proliferation. Current data, experimental treatments and perspectives], J Mal Vasc, vol.28, pp.130-174, 2003. ,
Ultrastructural characteristics of human atherectomy tissue from coronary and lower extremity arterial stenoses, The American Journal of Cardiology, vol.77, issue.7, pp.468-74, 1996. ,
DOI : 10.1016/S0002-9149(97)89339-3
The L utonix ?? drug-coated balloon: A novel drug delivery technology for the treatment of vascular disease, Advanced Drug Delivery Reviews, vol.112, pp.78-87, 2017. ,
DOI : 10.1016/j.addr.2017.05.015
Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. A study in the atherosclerotic rabbit, Circulation, vol.80, issue.4, pp.1029-1040, 1989. ,
DOI : 10.1161/01.CIR.80.4.1029
Drug eluting stents: an updated meta-analysis of randomised controlled trials, Heart, vol.92, issue.5, pp.641-650, 2006. ,
DOI : 10.1136/hrt.2005.061622
Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results, Circulation, vol.106, issue.12, pp.1505-1514, 2002. ,
DOI : 10.1161/01.CIR.0000029746.10018.36
Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial, J Endovasc Ther Off J Int Soc Endovasc Spec, vol.13, pp.701-711, 2006. ,
First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease, Journal of Vascular Surgery, vol.54, issue.2, pp.394-401, 2011. ,
DOI : 10.1016/j.jvs.2011.01.047
Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results, Circulation: Cardiovascular Interventions, vol.4, issue.5, pp.495-504, 2011. ,
DOI : 10.1161/CIRCINTERVENTIONS.111.962324
Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions, Journal of the American College of Cardiology, vol.61, issue.24, pp.2417-2444, 2013. ,
DOI : 10.1016/j.jacc.2013.03.034
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal ArteryCLINICAL PERSPECTIVE, Circulation, vol.133, issue.15, pp.1472-1483, 2016. ,
DOI : 10.1161/CIRCULATIONAHA.115.016900
Nitinol stents with polymerfree paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study, J Endovasc Ther Off J Int Soc Endovasc Spec, vol.18, pp.613-636, 2011. ,
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial, 2017. ,
Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries, Circulation, vol.94, issue.7, pp.1690-1697, 1996. ,
DOI : 10.1161/01.CIR.94.7.1690
Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis, Circulation, vol.110, issue.7, pp.810-814, 2004. ,
DOI : 10.1161/01.CIR.0000138929.71660.E0
Optimization of drug-eluting balloon use for safety and efficacy: Evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries, Catheterization and Cardiovascular Interventions, vol.64, issue.3, pp.395-403, 2010. ,
DOI : 10.1002/ccd.22468
Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications, Circulation, vol.115, issue.8, pp.1051-1059, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.106.675934
Molecular Basis of Restenosis and Drug-Eluting Stents, Circulation, vol.111, issue.17, pp.2257-73, 2005. ,
DOI : 10.1161/01.CIR.0000163587.36485.A7
Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation, Journal of the American College of Cardiology, vol.42, issue.8, pp.1415-1435, 2003. ,
DOI : 10.1016/S0735-1097(03)01056-8
Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg, New England Journal of Medicine, vol.358, issue.7, pp.689-699, 2008. ,
DOI : 10.1056/NEJMoa0706356
Techniques endovasculaires de base en chirurgie vasculaire, 2014. ,
Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery, Circulation, vol.96, issue.2, pp.636-681, 1997. ,
DOI : 10.1161/01.CIR.96.2.636
In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons, European Journal of Pharmaceutics and Biopharmaceutics, vol.96, 2015. ,
DOI : 10.1016/j.ejpb.2015.08.010
Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing, Open Heart, vol.66, issue.1, p.117, 2014. ,
DOI : 10.1158/0008-5472.CAN-05-3885
Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing, JACC: Cardiovascular Interventions, vol.8, issue.8, pp.1115-1138, 2015. ,
DOI : 10.1016/j.jcin.2015.03.020
Correlating Coating Characteristics with the Performance of Drug-Coated Balloons ??? A Comparative In Vitro Investigation of Own Established Hydrogel- and Ionic Liquid-Based Coating Matrices, PLOS ONE, vol.50, issue.5, 2015. ,
DOI : 10.1371/journal.pone.0116080.s001
Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model, Clinical Research in Cardiology, vol.358, issue.5, pp.325-355, 2009. ,
DOI : 10.1161/01.CIR.103.18.2289
Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel?, Circulation: Cardiovascular Interventions, vol.5, issue.3, pp.392-400, 2012. ,
DOI : 10.1161/CIRCINTERVENTIONS.111.967794
Dose Response to Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Overstretch and Stent Implantation Model, Investigative Radiology, vol.46, issue.4, pp.255-63, 2011. ,
DOI : 10.1097/RLI.0b013e31820577df
Plasma Levels Following Application of Paclitaxel-Coated Balloon Catheters in Patients with Stenotic or??Occluded Femoropopliteal Arteries, R??Fo - Fortschritte auf dem Gebiet der R??ntgenstrahlen und der bildgebenden Verfahren, vol.183, issue.05, pp.448-55, 2011. ,
DOI : 10.1055/s-0029-1246028
Drug-Eluting Balloons for the Treatment of??the Superficial Femoral Artery In-Stent Restenosis, JACC: Cardiovascular Interventions, vol.7, issue.4, 2014. ,
DOI : 10.1016/j.jcin.2013.11.020
Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent RestenosisCLINICAL PERSPECTIVE, Circulation, vol.132, issue.23, pp.2230-2236, 2015. ,
DOI : 10.1161/CIRCULATIONAHA.115.017364
Classification and Clinical Impact of Restenosis After Femoropopliteal Stenting, Journal of the American College of Cardiology, vol.59, issue.1, pp.16-23, 2012. ,
DOI : 10.1016/j.jacc.2011.09.036
Conventional Balloon Angioplasty versus Peripheral Cutting Balloon Angioplasty for Treatment of Femoropopliteal Artery In-Stent Restenosis: Initial Experience, Radiology, vol.248, issue.1, pp.297-302, 2008. ,
DOI : 10.1148/radiol.2481071159
Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: A retrospective review from a single center, Cardiovascular Revascularization Medicine, vol.13, issue.4, pp.224-231, 2012. ,
DOI : 10.1016/j.carrev.2012.03.004
Safety and One-Year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: A retrospective review from a single center, Cardiovascular Revascularization Medicine, vol.13, issue.6, pp.341-345, 2012. ,
DOI : 10.1016/j.carrev.2012.08.012
Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery, J Cardiovasc Surg (Torino), vol.51, pp.551-60, 2010. ,
Long-term results after directional atherectomy of femoro-popliteal lesions, J Am Coll Cardiol, vol.48, 2006. ,
Endovascular Brachytherapy Using Liquid Beta-Emitting Rhenium-188 for the Treatment of Long-Segment Femoropopliteal In-Stent Stenosis, Journal of Endovascular Therapy, vol.19, issue.4, pp.467-75, 2012. ,
DOI : 10.1583/12-3832R.1
Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis, JACC: Cardiovascular Interventions, vol.8, issue.1 ,
DOI : 10.1016/j.jcin.2014.09.009
Superiority of Stent-Grafts for In-Stent Restenosis in the Superficial Femoral Artery, Journal of Endovascular Therapy, vol.60, issue.1, pp.1-1010, 2015. ,
DOI : 10.1016/j.jacc.2012.07.033
Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial, Circulation, vol.118, issue.13, pp.1358-65, 2008. ,
DOI : 10.1161/CIRCULATIONAHA.107.735985
Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial, Circulation, vol.131, issue.5, pp.495-502, 2015. ,
DOI : 10.1161/CIRCULATIONAHA.114.011004
Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions, Journal of the American College of Cardiology, vol.66, issue.21, pp.2329-2367, 2015. ,
DOI : 10.1016/j.jacc.2015.09.063
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease, New England Journal of Medicine, vol.373, issue.2, pp.145-53, 2015. ,
DOI : 10.1056/NEJMoa1406235
Low-Dose Paclitaxel???Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery DiseaseClinical Perspective, Circulation, vol.135, issue.23, pp.2227-2263, 2017. ,
DOI : 10.1161/CIRCULATIONAHA.116.026493
The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization, JACC: Cardiovascular Interventions, vol.7, issue.1, pp.10-19, 2014. ,
DOI : 10.1016/j.jcin.2013.05.022
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease, Circulation, vol.136, issue.12 ,
DOI : 10.1161/CIRCULATIONAHA.117.028893
Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient, Journal of Endovascular Therapy, vol.5, issue.1, pp.14-21, 2015. ,
DOI : 10.1161/CIRCINTERVENTIONS.111.962324
Acotec Drug-Coated Balloon Catheter, JACC: Cardiovascular Interventions, vol.9, issue.18, 2016. ,
DOI : 10.1016/j.jcin.2016.06.055
Clinical Evaluation of a Paclitaxel-Eluting Balloon for Treatment of Femoropopliteal Arterial Disease, JACC: Cardiovascular Interventions, vol.5, issue.3, 2012. ,
DOI : 10.1016/j.jcin.2011.11.010
1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery??Disease, JACC: Cardiovascular Interventions, vol.9, issue.9, pp.950-956, 2016. ,
DOI : 10.1016/j.jcin.2016.02.014
Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first-in-human study, Catheterization and Cardiovascular Interventions, vol.37, issue.2, pp.278-86, 2015. ,
DOI : 10.1007/s00270-014-0904-3
The Lutonix EU Long Lesion study: A Prospective, Multicenter, Single-Arm Trial with the Lutonix® Drug Coated Balloon for Treatment of Long Lesions in Femoropopliteal Arteries, 2017. ,
PACT drug-coated balloon: Consistent clinical outcomes across patient populations and challenging lesions, 2017. ,
Optimal DCB Performance : LEVANT 2 and Global SFA Real-World Registry, 2016. ,
Peripheral Arterial Balloon Angioplasty: Effect of Short versus Long Balloon Inflation Times on the Morphologic Results, Journal of Vascular and Interventional Radiology, vol.13, issue.4, pp.355-364, 2002. ,
DOI : 10.1016/S1051-0443(07)61736-9
Smooth Muscle Cell Proliferation in the Arterial Intima after Stretch Injury: Relationship between the Severity of Stretching and Intima Hyperplasia in New Zealand White Rabbits, Experimental Animals, vol.45, issue.1, pp.89-93, 1996. ,
DOI : 10.1538/expanim.45.89
German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease, Journal of Endovascular Therapy, vol.169, issue.3, pp.409-1610, 2016. ,
DOI : 10.1016/j.ahj.2014.11.016
Latest Insights from the LEVANT II study and sub-group analysis, 2016. ,
Drug-Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery, JACC: Cardiovascular Interventions, vol.6, issue.12, pp.1295-302, 2013. ,
DOI : 10.1016/j.jcin.2013.07.010
High-grade, non-flowlimiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study, J Endovasc Ther Off J Int Soc Endovasc Spec, vol.201, pp.792-800, 2013. ,
Contemporary outcomes after superficial femoral artery angioplasty and stenting: The influence of TASC classification and runoff score, Journal of Vascular Surgery, vol.47, issue.5, pp.967-74, 2008. ,
DOI : 10.1016/j.jvs.2007.12.050
2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery??Disease, JACC: Cardiovascular Interventions, vol.10, issue.7, pp.728-762, 2017. ,
DOI : 10.1016/j.jcin.2017.01.028
DCB and restenosis: who fails and why? What we do about it now and what the future holds, 2017. ,
Drug-Coated Balloons for Complex Femoropopliteal Lesions, JACC: Cardiovascular Interventions, vol.9, issue.7, pp.715-739, 2016. ,
DOI : 10.1016/j.jcin.2015.12.267
Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis, Journal of Vascular Surgery, vol.61, issue.2, pp.394-403, 2015. ,
DOI : 10.1016/j.jvs.2014.08.005
Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries, Journal of Vascular Surgery, vol.58, issue.3, pp.682-688, 2013. ,
DOI : 10.1016/j.jvs.2013.02.019
Treatment of Chronic SFA In-Stent Occlusion With Combined Laser Atherectomy and Drug-Eluting Balloon Angioplasty in Patients With Critical Limb Ischemia: A Single-Center, Prospective, Randomized Study, Journal of Endovascular Therapy, vol.20, issue.6, pp.805-819, 2013. ,
DOI : 10.1583/13-4308MR.1
Calcium Burden Assessment and Impact on Drug-Eluting Balloons in Peripheral Arterial Disease, CardioVascular and Interventional Radiology, vol.37, issue.5, pp.898-907, 2014. ,
DOI : 10.1016/S0735-1097(01)01175-5
Current status of drug coated balloon treatment in the SFA: What do the 3 year outcomes from the IN.PACT SFA RCT tell us, 2017. ,
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease, Journal of Vascular Surgery, vol.64, issue.5, pp.1503-1517, 2016. ,
DOI : 10.1016/j.jvs.2016.05.084
2-Year Results of Paclitaxel-Eluting Balloons for Femoropopliteal Artery Disease, JACC: Cardiovascular Interventions, vol.6, issue.3, pp.282-291, 2013. ,
DOI : 10.1016/j.jcin.2013.01.128
The 24-Month Results of the Lutonix??Global SFA Registry, JACC: Cardiovascular Interventions, vol.10, issue.16, 2017. ,
DOI : 10.1016/j.jcin.2017.04.041
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease, Journal of Vascular Surgery, vol.64, issue.5, pp.1503-1517, 2016. ,
DOI : 10.1016/j.jvs.2016.05.084
Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty, Journal of Vascular Surgery, vol.65, issue.2, pp.558-570, 2017. ,
DOI : 10.1016/j.jvs.2016.10.089
Drug-Coated Balloon Versus Plain Balloon??Angioplasty for the Treatment of??Femoropopliteal Artery Disease, JACC: Cardiovascular Interventions, vol.9, issue.16, pp.1731-1773, 2016. ,
DOI : 10.1016/j.jcin.2016.06.008
Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials, Circulation: Cardiovascular Interventions, vol.5, issue.4, pp.582-591, 2012. ,
DOI : 10.1161/CIRCINTERVENTIONS.112.969972
Angioplasty of femoralpopliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial, JACC Cardiovasc Interv, vol.8, 2015. ,
2-year results of the AcoArt I - RCT for the Use of the Orchid ® DCB in Femoral popliteal Artery Disease, 2017. ,
Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine, Journal of Vascular and Interventional Radiology, vol.27, issue.11, 2016. ,
DOI : 10.1016/j.jvir.2016.06.036
A study of downstream events of the two leading DCBs on the market, 2017. ,
Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery, Journal of Vascular Surgery, vol.59, issue.4, 2014. ,
DOI : 10.1016/j.jvs.2014.01.041
Role of vessel preparation in contemporary DCB practice, 2017. ,
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease, New England Journal of Medicine, vol.373, issue.2, pp.145-53, 2015. ,
DOI : 10.1056/NEJMoa1406235
6-month Results of the RANGER SFA Randomized Study of the Ranger Paclitaxel- Coated Balloon: Diabetic Subgroup, 2017. ,
Final angiographic and clinical 12-month results of the CONSEQUENT trial, 2017. ,
2-year result of the REAL PTX - randomized clinical trial comparing Zilver PTX vs. DCB treatment in femoropoliteal lesions, 2017. ,
Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease, Catheterization and Cardiovascular Interventions, vol.45, issue.6, pp.1078-85, 2017. ,
DOI : 10.1016/j.jacc.2004.11.026
Repetetive DCB treatment for femoropopliteal lesions ? a viable solution for recurrent lesions? LINC, 2017. ,
Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany, Catheterization and Cardiovascular Interventions, vol.61, issue.4, pp.546-54, 2014. ,
DOI : 10.1016/j.jacc.2013.03.034
Critical appraisal of paclitaxel balloon angioplasty for femoral–popliteal arterial disease, Vascular Health and Risk Management, vol.12, pp.341-56, 2016. ,
DOI : 10.2147/VHRM.S81122
Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons??Versus Standard Percutaneous Transluminal Angioplasty, JACC: Cardiovascular Interventions, vol.9, issue.22, pp.2343-52, 2016. ,
DOI : 10.1016/j.jcin.2016.08.036
Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document, European Heart Journal, vol.37, issue.14, pp.1096-103, 2016. ,
DOI : 10.1093/eurheartj/ehv204
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS), European Heart Journal ,
DOI : 10.1093/eurheartj/ehx095
Treatment strategies for SFA disease. LINC 2016 ,
être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité. Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux ,
sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité ,